CENTER FOR PHARMACOECONOMICS
A division of MEDACorp
Offering Evaluation and Perspective on the Impact of Innovation
Contact UsCommunicating the societal impact of healthcare innovation in the United States.
The Leerink Center for Pharmacoeconomics (CPE) intends to be the storyteller of healthcare innovation. We provide commentaries, analyses, and advice to help the industry understand the long-term societal impact of healthcare innovations. Answering calls from academic experts and professional health economic societies, we champion a broader view of treatment value.
Through our thought leadership, evaluations, and advisory services, CPE will be a catalyst for change in the healthcare industry. By highlighting the societal value of healthcare innovation, we hope to shape the future of healthcare, contributing to better societal outcomes and ongoing innovation.
More About CPE
In an era where healthcare costs are under intense scrutiny, the need to understand the value of pharmaceutical innovation is crucial. CPE specializes in educating, evaluating, and advising on the societal impacts of healthcare innovation, focusing on a broader view of value. Our approach considers not only the healthcare costs and health benefits of a treatment, but also its impact on society to promote healthcare innovation and foster meaningful advancements in pharmaceutical evaluation.
-
What We Do
Educate the Industry: We provide commentary and curate resources on debates and themes within value assessment to shape a future where healthcare innovations are celebrated and societal outcomes are prioritized.
Evaluate Healthcare Innovation: We conduct evaluations of in-development and approved healthcare treatments using innovative methods that account for the broader societal impacts of healthcare treatments to foster healthcare innovation and improve societal outcomes.
Engage Innovators: We offer expert advice on how to best demonstrate the value of healthcare innovations through evidence and evaluation so the value proposition resonates with stakeholders.
Leerink Center for Pharmacoeconomics Management
Melanie (Mel) Whittington is a Managing Director and Head of the Center for Pharmacoeconomics, where she leads efforts to demonstrate the societal impacts of healthcare treatments in the US. As a thought leader in health economics, Dr. Whittington develops cost-effectiveness analyses of both in-development and approved pharmaceuticals from a societal perspective, and offers guidance on key components and novel methodologies.
Prior to joining MEDACorp in 2024, Dr. Whittington was the Managing Director and Founder of Valusphere, a health economic consultancy that developed economic evaluations, advised on value demonstration, and provided training to value assessment stakeholders. Previously to Valusphere, she was the Director of Health Economics at the Institute for Clinical and Economic Review where she led the design and development of economic evaluations and was faculty within the School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus. She is a Senior Fellow within the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center and has published more than 70 articles.
Dr. Whittington earned a PhD in Health Services Research from the University of Colorado Anschutz Medical Campus, an MS in Health Sciences from Western Illinois University, and a BS in Biological Sciences from the University of Missouri.
